WO2000059499A1 - Utilisation d'acide succinique ou de ses sels dans le traitement du diabete et la cicatrisation de blessures - Google Patents
Utilisation d'acide succinique ou de ses sels dans le traitement du diabete et la cicatrisation de blessures Download PDFInfo
- Publication number
- WO2000059499A1 WO2000059499A1 PCT/RU1999/000100 RU9900100W WO0059499A1 WO 2000059499 A1 WO2000059499 A1 WO 2000059499A1 RU 9900100 W RU9900100 W RU 9900100W WO 0059499 A1 WO0059499 A1 WO 0059499A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- succinic acid
- pharmaceutically acceptable
- acceptable salt
- insulin
- signal transduction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
Definitions
- Diabetes and systemic glucocorticoid treatment caused a severe defect in wound healing accompanied by reduced expression of PDGF receptors. Beer, H.D. et al., I Invest. Dermatol. 109:132-8(1997).
- the levels of IGF-1 was reported to be reduced in the wound enviroment of diabetics, whereas treatment of these wounds with IGF-1 reverses diabetes-induced wound healing impairment.
- Wound healing is impaired under ageing due to delay in appearance of growth factors such as PDGF, EGF and their receptors in the wound enviroment. Ashcroft, G.S. et al., J. Anat.
- PTPases of the invention play a role in cellular signal transduction.
- the inhibiting PTPase activity by succinic acid or a pharmaceutically acceptable salt thereof is useful for modulating signal transduction and regulation cellular processes which are governed by signal transduction.
- signal transduction includes the multiple pathways that are regulated by reversible phosphorylation of specific tyrosine residues on proteins involved in signaling.
- modulating means upregulation or downregulation of a signaling pathway.
- Cellular processes under the control of signal transduction may include, but are not limited to, normal processes such as proliferation, differentiation, transcription of specific genes, adhesion, apoptosis, and survival; and abnormal processes such as transformation, and blocking differentiation.
- Dysfunctional signal transduction can result from imbalance between activity of PTPases and proteine tyrosine kinases which play roles in a signaling pathway.
- the disease states may be caused by dysfunctional signal transduction of insulin receptor, members of insulin-like growth factor receptor family, epidermal growth factor receptor family, transforming growth factor receptor family, fibroblast growth factor receptor family, hepatocyte growth factor receptor family, vascular endothelial growth factor receptor family, transforming growth factor, platelet-derived growth factor receptor, the T-cell receptor, the B-cell receptor, members of the type 2 to 4 cytokine receptor families, and erythropoietin receptor.
- the present invention provides a method of treating wounds, which comprises administering to a mammal in need thereof an effective amount of succinic acid or a pharmaceutically acceptable salt thereof.
- wounds may include, but are not limited to, incised wounds, burn wounds, gastrointenstinal mucosal erosions and ulcers, periodontal wounds, and bone fractures.
- the invention provides a method of treating disease state caused by dysfunctional signal transduction in a mammal, which comprises administering to a mammal in need thereof an effective amount of succinic acid or a pharmaceutically acceptable salt thereof stepwise or in physical combination with an effective amount of a protein tyrosine kinase activator.
- receptor include but are not limited to, insulin receptor, members of insulin-like growth factor receptor family, epidermal growth factor receptor family, fibroblast growth factor receptor family, hepatocyte growth factor receptor family, vascular endothelial growth factor receptor family, nerve growth factor, platelet-derived growth factor, the T-cell receptor, the B-cell receptor, members of the type 2 to 4 cytokine receptor families, and erythropoietin receptor.
- the invention provides for the use of succinic acid or a pharmaceutically acceptable salt thereof for the manufacture of a medicament or a nutritional supplement effective for treating disease state caused by dysfunctional signal transduction in a mammal, preferably in a human.
- Succinic acid or a pharmaceutically acceptable salt thereof is useful in nutritional and medicinal formulations according to the present invention for treating disease state caused by dysfunctional signal transduction in a mammal, preferably in a human.
- the medicament or nutritional supplement of the invention is prepared by known procedures using well-known ingredients. In making the medicament or nutritional supplement, the active ingredients will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, and may be in the form of a capsule, tablet, paper or other container.
- the carrier When the carrier serves as a diluent, it may be a solid, semisolid, or liquid material which acts as a vehicle, excipient, or medium for the active ingredient.
- the nutritional supplements can be in the form of tablets, pills, powders, elixirs, suspensions, emulsions, solutions, syrups, soft and hard gelatin capsules.
- the medicament can be in the form of tablets, pills, powders, elixirs, suspensions, emulsions, solutions, syrups, soft and hard gelatin capsules, aerosoles, suppositories, sterile injectable solutions, and sterile packaged powders.
- suitable carriers include lactose, dextrose, sorbitol, mannitol, calcium phosphate, alginates, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyl and propyl hydroxybenzoates, talc, magnesium stearate, stearic acid, and mineral oil.
- the medicaments or nutritional supplements can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents.
- the orally ingestible nutritional supplement of the invention can comprise deionized water, succinic acid or salt thereof, maltodextrin, sodium caseinate, corn syrup solids, medium chain triglycerides, canola oil, calcium caseinate, soy protein, potassium citrate, magnesium chloride, sodium citrate, tricalcium phosphate, soy lecithine, sodium invention is synergistically effective in downregulating signal transduction that normally downregulated by dephosphorylation of phosphotyrosine residues in proteins involved in signaling pathways.
- the protein tyrosine kinase activator of the composition is insulin.
- Insulin of the invention is any standard insulin prepared by methods well-known in the art.
- the new combination of succinic acid or a pharmaceutically acceptable salt thereof with insulin is synergistically effective in triggering or enhancing insulin receptor signal transduction that is accordingly effective for treating disease states caused by dysfunctional signal transduction of insulin receptor.
- the disease states caused by dysfunctional insulin receptor signal transduction is diabetes mellitus.
- Insulin is administered parenterally in the method of the invention.
- the effective amount of insulin is selected from 2 units to 100 units per day per mammalian subject.
- the mammal of the invention is a human.
- the succinic acid has the chemical structure given below:
- mice Male albino Wistar rats 8-10 weeks of age 200-250 grams of body weight were used. The rats were housed at the temperature of 18 ⁇ 21°C on a 12 hour light-dark cycle. Rats were fed on a stock laboratory diet (59 % carbohydrates; 17 % protein; 3 % fat; 21 % minerals, water, cellulose) and allowed water ad libitum.
- Adipocytes preparation Isolated rat adipocytes were prepared by the method of
- Rat livers were washed with cold phosphate- buffered saline and homogenized in buffer containing 100 mM Tris-HCl, 1.15% KCl, and pH 7.4. The homogenate was centrifuged at 200 g for 10 min to remove debris, and a postnuclear supernatant (35.6 mg of protein per ml) was used in the experiments.
- Disodium succinate hexahydrate was assayed for its activity in inhibiting PTPase activity in the cellular fractions (rat adipocytes and liver supernatant).
- the PTPase assay 60 ⁇ l of the cell fraction was incubated in 40 ⁇ l of a reaction buffer containing 50 mM Tris/HCl, pH 7.5 and 10 mM phosphotyrosine as the substrate, and with or without (control) 2 mM disodium succinate hexahydrate. After a 5, 10, or 20 min incubation period at 37°C, the reaction was terminated by the addition of 40 ⁇ l 10% BSA and 120 ⁇ l 25% tricloroacetic acid.
- EXAMPLE 2 This example shows that administering disodium succinate mimics insulin in totally pancreatectomized rats.
- Plasma triglycerides and cholesterol concentrations in High Density Lipoprotein (HDL) and Low Density Lipoprotein (LDL) were determined by enzymatic methods with kits (Boeringher Mannheim, Mannheim, Germany) with Multistat 3 F LS apparatus (Instrumentation Laboratories, Lexington, USA).
- NIDDM humans were metabolically stable and had fasting glucose levels more than
- This example shows that administering an effective amount of disodium salt of succinic acid is effective for treating wounds.
- a suppurative wounds were prepared by the method of Eliseev. Eliseev, N.G. "Connective tissue", Moscow (1961).
- the 30 male Wistar rats maintained as described in example 1 of the invention were used in this experiment.
- the rats were anaesthetized with 1% solution of nembutal (0.2 ml/100 g of body weight, intramuscularly). Incisions of 15 to 20 mm length in inguinal region of rats were made.
- a four celluloid balls of 2 mm diameter were entered into the each wound.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99933303A EP1165063A1 (fr) | 1999-04-05 | 1999-04-05 | Utilisation d'acide succinique ou de ses sels dans le traitement du diabete et la cicatrisation de blessures |
PCT/RU1999/000100 WO2000059499A1 (fr) | 1999-04-05 | 1999-04-05 | Utilisation d'acide succinique ou de ses sels dans le traitement du diabete et la cicatrisation de blessures |
AU49376/99A AU4937699A (en) | 1999-04-05 | 1999-04-05 | Use of succinic acid or salts thereof for the treatment of diabetes mellitus andwound healing |
CA002362116A CA2362116A1 (fr) | 1999-04-05 | 1999-04-05 | Utilisation d'acide succinique ou de ses sels dans le traitement du diabete et la cicatrisation de blessures |
IL14570100A IL145701A0 (en) | 1999-04-02 | 2000-03-31 | Purine derivatives having phosphodiesterase iv inhibition activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU1999/000100 WO2000059499A1 (fr) | 1999-04-05 | 1999-04-05 | Utilisation d'acide succinique ou de ses sels dans le traitement du diabete et la cicatrisation de blessures |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000059499A1 true WO2000059499A1 (fr) | 2000-10-12 |
Family
ID=20130334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU1999/000100 WO2000059499A1 (fr) | 1999-04-02 | 1999-04-05 | Utilisation d'acide succinique ou de ses sels dans le traitement du diabete et la cicatrisation de blessures |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1165063A1 (fr) |
AU (1) | AU4937699A (fr) |
CA (1) | CA2362116A1 (fr) |
WO (1) | WO2000059499A1 (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001076583A1 (fr) * | 2000-04-10 | 2001-10-18 | Verteletsky, Pavel Vasilievich | Compositions synergiques contenant une base de choline et de l'acide succinique pour traiter l'insulinoresistance et le diabete |
WO2002098414A1 (fr) * | 2001-06-07 | 2002-12-12 | Wyeth | Procedes d'utilisation d'inhibiteurs de ptpase et d'insuline |
WO2003006072A1 (fr) * | 2001-07-10 | 2003-01-23 | Penam Investments Pty Ltd | Procede de traitement et/ou de prophylaxie des ulceres |
WO2003055476A1 (fr) * | 2001-12-25 | 2003-07-10 | Pomytkin Igor A | Utilisation d'acide succinique et de ses sels dans l'inhibition de l'agregation plaquetaire |
WO2004112773A1 (fr) * | 2003-04-24 | 2004-12-29 | Shin-Jen Shiao | Compositions pharmaceutiques utilisees pour le traitement de maladie immune et amelioration |
EP1682570A1 (fr) * | 2003-10-27 | 2006-07-26 | Medvet Science Pty. Ltd. | Motif de liaison et methodes de regulation d'une fonction cellulaire |
AU2002344698B2 (en) * | 2001-07-10 | 2006-07-27 | Penam Investments Pty Ltd | A method of treatment and/or prophylaxis of ulcers |
WO2008099742A2 (fr) * | 2007-02-16 | 2008-08-21 | Canon Kabushiki Kaisha | Liquide d'éjection et procédé d'éjection |
WO2019244133A1 (fr) | 2018-06-22 | 2019-12-26 | Enzene Biosciences Limited | Acide succinique et dérivés destinés au traitement de troubles hématologiques |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56125312A (en) * | 1980-03-09 | 1981-10-01 | Lion Corp | Remedy for damage |
JPS61171417A (ja) * | 1985-01-23 | 1986-08-02 | Wakunaga Seiyaku Kk | 抗糖尿病剤 |
JPH03236320A (ja) * | 1990-02-09 | 1991-10-22 | Kobayashi Kose Co Ltd | 皮膚外用剤 |
JPH0662798A (ja) * | 1992-08-19 | 1994-03-08 | Nakano Vinegar Co Ltd | 低耐糖能者用食品 |
JPH09124472A (ja) * | 1995-10-27 | 1997-05-13 | Noevir Co Ltd | コラゲナーゼ阻害剤 |
WO1997048414A1 (fr) * | 1996-06-20 | 1997-12-24 | Novo Nordisk A/S | Preparations d'insuline contenant du nacl |
-
1999
- 1999-04-05 AU AU49376/99A patent/AU4937699A/en not_active Abandoned
- 1999-04-05 EP EP99933303A patent/EP1165063A1/fr not_active Withdrawn
- 1999-04-05 WO PCT/RU1999/000100 patent/WO2000059499A1/fr not_active Application Discontinuation
- 1999-04-05 CA CA002362116A patent/CA2362116A1/fr not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56125312A (en) * | 1980-03-09 | 1981-10-01 | Lion Corp | Remedy for damage |
JPS61171417A (ja) * | 1985-01-23 | 1986-08-02 | Wakunaga Seiyaku Kk | 抗糖尿病剤 |
JPH03236320A (ja) * | 1990-02-09 | 1991-10-22 | Kobayashi Kose Co Ltd | 皮膚外用剤 |
JPH0662798A (ja) * | 1992-08-19 | 1994-03-08 | Nakano Vinegar Co Ltd | 低耐糖能者用食品 |
JPH09124472A (ja) * | 1995-10-27 | 1997-05-13 | Noevir Co Ltd | コラゲナーゼ阻害剤 |
WO1997048414A1 (fr) * | 1996-06-20 | 1997-12-24 | Novo Nordisk A/S | Preparations d'insuline contenant du nacl |
Non-Patent Citations (14)
Title |
---|
DATABASE WPI Section Ch Week 198146, Derwent World Patents Index; Class B05, AN 1981-84297D, XP002123542 * |
DATABASE WPI Section Ch Week 198637, Derwent World Patents Index; Class B05, AN 1986-242355, XP002123544 * |
DATABASE WPI Section Ch Week 199148, Derwent World Patents Index; Class B03, AN 1991-350854, XP002123543 * |
DATABASE WPI Section Ch Week 199414, Derwent World Patents Index; Class B05, AN 1994-114217, XP002123541 * |
DZVONKEVYCH, GULY: "Effects of Carboxylin, Acetate and Acids of the Tricarboxylic Cycle on the Content of Glucose in Blood and Citric acid in Urine of Rabbits with Alloxan Diabetes.", UKR. BIOKHIM. ZH., vol. 46, no. 5, 1974, pages 547 - 552, XP002123538 * |
EBIHARA, KIYOSHI ET AL: "Comparative effects of various organic acids on glucose-flattening activity in rats fed a glucose solution", NUTR. REP. INT. (1989), 40(5), 1041-7, XP002123534 * |
KOREC, R.: "Succinic acid alkyl esters-new genericoral anti-diabetic agents in alloxan and STZ diabetic rats", DIABETOLOGIA, vol. 40, no. suppl. 1, 1997, pages A375, XP002123539 * |
LAMBERT, ANDRE E. ET AL: "Organ culture of fetal rat pancreas. II. Insulin release induced by amino and organic acids, by hormonal peptides, by cationic alterations of the medium, and by other agents", BIOCHIM. BIOPHYS. ACTA (1969), 184(3), 540-53, XP002123536 * |
LANGTRY JA ET AL: "Topical lithium succinate ointment (Efalith) in the treatment of AIDS-related seborrhoeic dermatitis", CLINICAL AND EXPERIMENTAL DERMATOLOGY,GB,BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, vol. 22, no. 5, pages 216-219, XP002105249, ISSN: 0307-6938 * |
LECLERCQ-MEYER, V.; MALAISSE, W.J.: "Potentiation of GLP-1 Insulinotropic Action by a Nonglucidic Nutrient in the pancreas of Diabetic GK Rats.", BIOCHEMICAL AND MOLECULAR MEDICINE, vol. 59, no. 1, 1996, pages 87 - 90, XP002123540 * |
MACDONALD, MICHAEL J. ET AL: "Glyceraldehyde phosphate and methyl esters of succinic acid. Two "new" potent insulin secretagogues", DIABETES (1988), 37(7), 997-9, XP002123535 * |
MALAISSE WILLY: "Insulinotropic Nutritient Esters", DRUGS FUTURE, vol. 23, no. 11, 1998, pages 1205 - 1216, XP002123537 * |
MIYAMOTO ET AL.: "Effects of cosmetics containing Bioactive substances on skin", JOURNAL OF THE SOCIETY OF COSMETIC CHEMISTS OF JAPAN, vol. 22, no. 4, 1989, pages 254 - 262, XP000856450 * |
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 09 30 September 1997 (1997-09-30) * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001076583A1 (fr) * | 2000-04-10 | 2001-10-18 | Verteletsky, Pavel Vasilievich | Compositions synergiques contenant une base de choline et de l'acide succinique pour traiter l'insulinoresistance et le diabete |
WO2002098414A1 (fr) * | 2001-06-07 | 2002-12-12 | Wyeth | Procedes d'utilisation d'inhibiteurs de ptpase et d'insuline |
US6797693B2 (en) | 2001-06-07 | 2004-09-28 | Wyeth | Methods using PTPase inhibitors and insulin |
AU2002344698B2 (en) * | 2001-07-10 | 2006-07-27 | Penam Investments Pty Ltd | A method of treatment and/or prophylaxis of ulcers |
WO2003006072A1 (fr) * | 2001-07-10 | 2003-01-23 | Penam Investments Pty Ltd | Procede de traitement et/ou de prophylaxie des ulceres |
WO2003055476A1 (fr) * | 2001-12-25 | 2003-07-10 | Pomytkin Igor A | Utilisation d'acide succinique et de ses sels dans l'inhibition de l'agregation plaquetaire |
WO2004112773A1 (fr) * | 2003-04-24 | 2004-12-29 | Shin-Jen Shiao | Compositions pharmaceutiques utilisees pour le traitement de maladie immune et amelioration |
EP1682570A1 (fr) * | 2003-10-27 | 2006-07-26 | Medvet Science Pty. Ltd. | Motif de liaison et methodes de regulation d'une fonction cellulaire |
EP1682570A4 (fr) * | 2003-10-27 | 2006-12-06 | Medvet Science Pty Ltd | Motif de liaison et methodes de regulation d'une fonction cellulaire |
WO2008099742A2 (fr) * | 2007-02-16 | 2008-08-21 | Canon Kabushiki Kaisha | Liquide d'éjection et procédé d'éjection |
WO2008099742A3 (fr) * | 2007-02-16 | 2008-12-31 | Canon Kk | Liquide d'éjection et procédé d'éjection |
US20100319696A1 (en) * | 2007-02-16 | 2010-12-23 | Canon Kabushiki Kaisha | Ejection liquid and ejection method |
WO2019244133A1 (fr) | 2018-06-22 | 2019-12-26 | Enzene Biosciences Limited | Acide succinique et dérivés destinés au traitement de troubles hématologiques |
Also Published As
Publication number | Publication date |
---|---|
CA2362116A1 (fr) | 2000-10-12 |
EP1165063A1 (fr) | 2002-01-02 |
AU4937699A (en) | 2000-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019203820B2 (en) | Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution | |
Genc et al. | Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro | |
Mantovani et al. | The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression | |
US11890269B2 (en) | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances | |
US20060128643A1 (en) | Compositions containing a combination of a creatine compound and a second agent | |
AU2007203159B2 (en) | Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone | |
JP2005529938A (ja) | 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法 | |
US7115563B2 (en) | Composition and its therapeutic use | |
JP2024010082A (ja) | オートファジーおよびリポファジーを調節するためのβ-ヒドロキシ-β-メチルブチレート(HMB)の組成物および使用方法 | |
US20230028151A1 (en) | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for modulating autophagy and lipophagy | |
EP1165063A1 (fr) | Utilisation d'acide succinique ou de ses sels dans le traitement du diabete et la cicatrisation de blessures | |
US20060128671A1 (en) | Compositions containing a combination of a creatine compound and a second agent | |
US11273135B2 (en) | Methods for using stabilized sulforaphene | |
US20100166838A1 (en) | Methods And Compositions For Modulating Keratinocyte Function | |
Mathuria et al. | Ameliorative effect of curcumin on aflatoxin-induced toxicity in serum of mice | |
Zhang et al. | Potential therapeutic value of antioxidants for abnormal prolongation of QT interval and the associated arrhythmias in a rabbit model of diabetes | |
CN111315374A (zh) | 合成的赖氨酸类似物和模拟物的用于抗病毒用途的方法和组合物 | |
ES2951171T3 (es) | Nueva composición que contiene aminoácidos de cadena ramificada | |
Han et al. | A Deep Insight into Ferroptosis in Renal Disease: Facts and Perspectives | |
BR102022021083A2 (pt) | Composição alimentar, uso da referida composição para aumentar a imunidade e ter capacidade de desintoxicação para melhorar fatores de estilo de vida, produto alimentar que compreende a referida composição e kit | |
Johnson | Protection against Angiotensin II-induced endothelial dysfunction and hypertension via small molecule inhibitors of signal transducer and activator of transcription 3 | |
Arab et al. | Nutrient Requirements in Dental Surgery Wound Healing–Does it Matter? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999933303 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2362116 Country of ref document: CA Ref country code: CA Ref document number: 2362116 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09914751 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999933303 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999933303 Country of ref document: EP |